Empros Pharma results published in scientific journal

The companies have announced positive in-vivo proof-of-concept data for a powder-based intranasal vaccine candidate formulated with the AmorphOX technology. The data was generated under the collaboration between Orexo and Abera Biosciences entered in December 2024. The aim of the collaboration is to develop mucosal vaccines by combining Orexo’s powder-based drug delivery technology AmorphOX with Abera’s […]

A new clinical trial map is now accessible from the public website of the Clinical Trials Information System (CTIS).

Immunovia has announced additional results from the VERIFI study of its next-generation pancreatic cancer test, strengthening the company’s position as it prepares to launch the pancreatic cancer blood test commercially. 

The FDA has approved the company’s IND application to initiate the Phase I/II study Oncorella-1.

The company has announced the authorization of its Clinical Trial Application (CTA) from the regulatory authorities in four European countries under the European Union’s (EU) harmonised framework, for VIDAR-1, with Germany acting as the reference state.

Evaxion Biotech will further enhance the data package from its ongoing phase 2 trial with the company’s lead asset EVX-01 by extending the trial from two to three years.

Medivir has presented positive, final data from the phase 1b / 2a study of fostroxacitabine bralpamide (fostrox) + Lenvima in advanced liver cancer (hepatocellular carcinoma/HCC) at the EASL (European Association for the Study of the Liver) Liver Cancer Summit in Paris, France.